Postpartum hemorrhage: when uterotonics and sutures fail

Area of Science:

• Obstetrics and Gynecology
• Hematology
• Critical Care Medicine

Background:

• Postpartum hemorrhage (PPH) is a leading cause of maternal morbidity and mortality.
• Acute coagulopathy frequently complicates massive obstetric hemorrhage, often developing despite the absence of identifiable antenatal or intrapartum risk factors.
• The underlying causes of coagulopathy in PPH include hemodilution, hepatic dysfunction, and disseminated intravascular coagulation (DIC).

Purpose of the Study:

• To review the pathophysiology and management of coagulopathy in the context of massive postpartum hemorrhage.
• To highlight the current understanding of transfusion strategies and the role of specific hemostatic agents.
• To emphasize the importance of rapid laboratory diagnostics and expert hematological consultation in optimizing patient care.

Main Methods:

• Review of existing literature and clinical guidelines regarding PPH management.
• Discussion of the role of blood component therapy, including fibrinogen replacement and the use of recombinant activated factor VIIa (rFVIIa).
• Emphasis on the utility of timely coagulation laboratory results in guiding hemostatic interventions.

Main Results:

• Standard practice involves maintaining fibrinogen levels ≥ 100 mg/dL, but evidence suggests a higher threshold (≥ 400 mg/dL) may be necessary for PPH.
• rFVIIa has been utilized in refractory cases of severe PPH.
• Rapid and informative coagulation testing is essential for effective clinical decision-making, complementing clinical assessment.

Conclusions:

• Effective management of massive PPH requires a multifaceted approach addressing coagulopathy.
• Aggressive correction of hypofibrinogenemia and timely use of hemostatic agents are critical.
• The expertise of hematologists is invaluable in navigating complex hemostatic challenges during life-threatening obstetric hemorrhage.